A strategy to reduce cardiovascular disease by more than 80%
about
Has the DOTS strategy improved case finding or treatment success? An empirical assessmentOne Pill, Four Questions: What we Still need to Know about Reducing Cardiovascular Risk with Combination TherapyFixed-dose combination therapy for the prevention of cardiovascular diseaseFixed-dose combination therapy for the prevention of cardiovascular diseasePatient perceptions of quality of life with diabetes-related complications and treatmentsAspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsWhat is the best strategy for reducing deaths from heart disease?Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factorsAssessing the impact of heart failure specialist services on patient populationsAvailability and structure of primary medical care services and population health and health care indicators in EnglandPrevalence of cardiovascular risk factors in a middle-income country and estimated cost of a treatment strategy.Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular PolypillBarriers to preventive therapy for breast and other major cancers and strategies to improve uptakeWhat is the evidence base for diagnosing hypertension and for subsequent blood pressure treatment targets in the prevention of cardiovascular disease?A review of the relationship between leg power and selected chronic disease in older adultsBenefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesContributions of risk factors and medical care to cardiovascular mortality trendsTraditional Chinese Exercise for Cardiovascular Diseases: Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEMCoronary heart disease prevention: insights from modelling incremental cost effectivenessCardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicityPanacea in a pill?Aspirin for everyone older than 50? ForAntiplatelet therapy in ischemic strokeProspects and possible pitfalls of a preventive Polypill: confessions of a health promotion convertAdherence to medications by patients after acute coronary syndromesWhat's new in stroke prevention and treatmentA cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countriesCardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisMy health: whose responsibility? Low-dose aspirin and older peopleCoronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and womenNovel therapies for the prevention of strokePrimary prevention of cardiovascular disease: cost-effectiveness comparisonCost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of TanzaniaPremature coronary artery disease in Indians and its associated risk factorsFixed combination of losartan and hydrochlorothiazide and reduction of risk of strokeAspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treLong-term continuation on cardiovascular drug treatment in patients with coronary heart diseaseA novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials
P2860
Q21144342-85421712-A444-4421-8A93-F791BF3F5F73Q24194960-EF92673E-0F2B-41FE-9B64-CDBA761FA467Q24195065-46EFB10F-5D12-4300-91F2-826D3756DD80Q24198070-683E61CC-BFE9-499B-AA05-1AA0E78F163CQ24644699-3FD35ECF-FB23-4F87-A067-E3127A2FB06EQ24645391-7B6F3FEF-D9DF-4322-BFA3-6AC2DCDC8853Q24792163-5D8F7E8A-10C1-4042-AFA2-A6662FD031B8Q24795084-E435C6D7-4646-46A2-B69C-836C6C7ADA3EQ24796318-995ABBED-F81B-41F8-932A-5DAD19D84304Q24796348-76138A77-737C-4355-9340-01E8B1841A44Q24800817-C5C91047-A0BE-417A-AF1A-6F68DC11AB2BQ25255555-A79BF980-D53D-42C6-ABF9-2EB761B5B95DQ26753102-C7F6CFA2-6072-4757-9DCC-47DF5DED945FQ26774593-119FF779-B7BA-4D08-A755-44408C01EBBEQ26784487-CF8B23BE-FE08-465D-952B-2FC253678C83Q26849747-42F0FD0D-5041-42B3-A003-D084A2039AADQ26853571-AA461665-283B-4799-9A43-0F37B2B1CBC2Q27012592-B60CECF7-4302-4032-8E87-39130D9FC73CQ28066539-B3B1AAC8-72AF-42A8-86CB-070F3485A8B5Q28166022-4B9F0CDD-0DA9-43A2-BE8C-497E6F64D601Q28166294-4775D4EA-0267-4133-AB0A-B1E06F1F4B07Q28166985-10B564C4-DF87-4445-84C0-0825674139F3Q28167667-27E3B93A-16A0-495B-B7A8-C6BA5502C6B7Q28180812-5FDD0715-87BA-42B3-89F1-676968F7A665Q28184366-39B37FD0-1D9A-43C1-8D91-2CD90B918D12Q28185674-0B7D3D5F-A5CA-426F-8623-75D03D2B7F78Q28192360-E0AB1040-AF86-4887-9018-ED239BD475AAQ28194923-4F12F83B-C4EF-4029-AE55-5E5F60CD463FQ28196568-6D892751-7FD0-4BFB-8D78-42F40F3C33F5Q28200196-59FAC0F4-0A3E-4527-820D-8458DC0BE910Q28201631-0975EE45-0C4A-41BB-B644-BCF6142F008AQ28210662-C2A9FA5D-5BF1-438C-B23E-D11448DB007CQ28210724-B7DC3543-73CE-453B-93A0-B9DD8F07B84DQ28217877-AFBCE384-F0F4-4D35-8AD1-D496C91E612BQ28219296-23AD4581-5A7C-4277-884D-86952E686658Q28219336-B10D6806-D459-46FE-8004-5F7273A2C7F8Q28219593-8E8A894B-2805-4B23-93BD-169906F55569Q28220363-374912D3-0A72-49BA-97E1-33A474AE1CEAQ28220890-33330747-4D61-4A97-BF0B-C5C8F6C39BD9Q28472432-54F8079C-CC4A-4C88-8646-C89D2D936A45
P2860
A strategy to reduce cardiovascular disease by more than 80%
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A strategy to reduce cardiovascular disease by more than 80%
@ast
A strategy to reduce cardiovascular disease by more than 80%
@en
A strategy to reduce cardiovascular disease by more than 80%
@nl
type
label
A strategy to reduce cardiovascular disease by more than 80%
@ast
A strategy to reduce cardiovascular disease by more than 80%
@en
A strategy to reduce cardiovascular disease by more than 80%
@nl
prefLabel
A strategy to reduce cardiovascular disease by more than 80%
@ast
A strategy to reduce cardiovascular disease by more than 80%
@en
A strategy to reduce cardiovascular disease by more than 80%
@nl
P2860
P3181
P1433
P1476
A strategy to reduce cardiovascular disease by more than 80%
@en
P2093
P2860
P3181
P356
10.1136/BMJ.326.7404.1419
P407
P577
2003-06-28T00:00:00Z